SenesTech, Inc., a biotechnology company based in Delaware, has filed a Registration Statement with the U.S. Securities and Exchange Commission (SEC) on August 6, 2024, to register an additional 200,000 shares of common stock for issuance under its 2018 Equity Incentive Plan, as amended. This registration is in addition to the common stock previously registered under the plan through prior Registration Statements filed on various dates from 2018 to 2023. The company, which is classified as a non-accelerated filer and a smaller reporting company, incorporates by reference several documents including its Annual Report on Form 10-K for the year ended December 31, 2023, and its Quarterly Report for the quarter ended March 31, 2024. The filing includes the consent of its independent registered public accounting firm and legal counsel, and it is signed by key executives including President and CEO Joel L. Fruendt and CFO Thomas C. Chesterman.

SenesTech, Inc., a biotechnology company based in Delaware, has filed a Registration Statement with the U.S. Securities and Exchange Commission (SEC) on August 6, 2024, to register an additional 200,000 shares of common stock for issuance under its 2018 Equity Incentive Plan, as amended. This registration is in addition to the common stock previously registered under the plan through prior Registration Statements filed on various dates from 2018 to 2023. The company, which is classified as a non-accelerated filer and a smaller reporting company, incorporates by reference several documents including its Annual Report on Form 10-K for the year ended December 31, 2023, and its Quarterly Report for the quarter ended March 31, 2024. The filing includes the consent of its independent registered public accounting firm and legal counsel, and it is signed by key executives including President and CEO Joel L. Fruendt and CFO Thomas C. Chesterman.